Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

wave life sciences ltd - WVE

WVE

Close Chg Chg %
7.14 0.48 6.72%

Closed Market

7.62

+0.48 (6.72%)

Volume: 2.52M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Trade Now

Company Overview: wave life sciences ltd - WVE

WVE Key Data

Open

$7.14

 Day Range

7.12 - 7.68

52 Week Range

5.28 - 15.72

 Market Cap

$1.19B

Shares Outstanding

167.18M

 Public Float

134.97M

Beta

-1.72

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.74

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.39M

  

WVE Performance

1 Week
 
 -1.80%
 
1 Month
 
 -3.05%
 
3 Months
 
 -8.08%
 
1 Year
 
 -50.10%
 
5 Years
 
 -13.01%
 

WVE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About wave life sciences ltd - WVE

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

WVE At a Glance

Wave Life Sciences Ltd.
Marina One East Tower
Singapore, Central Singapore 018936
Phone 65-6236-3388 Revenue 108.30M
Industry Biotechnology Net Income -97,008,000.00
Sector Health Technology Employees 288
Fiscal Year-end 12 / 2025
View SEC Filings

WVE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 15.794
Price to Book Ratio 9.035
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -14.17
Enterprise Value to Sales 13.312
Total Debt to Enterprise Value 0.018

WVE Efficiency

Revenue/Employee 376,048.611
Income Per Employee -336,833.333
Receivables Turnover 76.162
Total Asset Turnover 0.345

WVE Liquidity

Current Ratio 2.888
Quick Ratio 2.888
Cash Ratio 2.723

WVE Profitability

Gross Margin 92.001
Operating Margin -101.94
Pretax Margin -89.572
Net Margin -89.572
Return on Assets -30.936
Return on Equity -73.243
Return on Total Capital -39.955
Return on Invested Capital -62.979

WVE Capital Structure

Total Debt to Total Equity 11.686
Total Debt to Total Capital 10.463
Total Debt to Total Assets 7.213
Long-Term Debt to Equity 8.48
Long-Term Debt to Total Capital 7.317
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Wave Life Sciences Ltd - WVE

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
40.96M 3.65M 113.31M 108.30M
Sales Growth
+104.03% -91.09% +3,005.10% -4.42%
Cost of Goods Sold (COGS) incl D&A
- 10.11M 9.21M 8.66M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
9.84M 10.11M 9.21M 8.66M
Depreciation
9.84M 10.11M 9.21M 8.66M
Amortization of Intangibles
- - - -
-
COGS Growth
- - -8.98% -5.90%
-
Gross Income
- (6.47M) 104.10M 99.64M
Gross Income Growth
- - +1,710.19% -4.28%
-
Gross Profit Margin
- -177.17% +91.88% +92.00%
2021 2022 2023 2024 5-year trend
SG&A Expense
158.15M 156.26M 172.10M 210.04M
Research & Development
121.88M 115.86M 130.01M 159.68M
Other SG&A
36.27M 40.40M 42.09M 50.36M
SGA Growth
-3.26% -1.20% +10.14% +22.05%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(127.02M) (162.72M) (68.00M) (110.40M)
Non Operating Income/Expense
4.57M 1.58M 9.81M 13.40M
Non-Operating Interest Income
30.00K 1.57M 7.93M 10.16M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(122.45M) (161.14M) (58.19M) (97.01M)
Pretax Income Growth
+18.77% -31.60% +63.89% -66.71%
Pretax Margin
-298.92% -4,416.06% -51.36% -89.57%
Income Tax
- (204.00K) 681.00K (677.00K)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- (204.00K) 681.00K (677.00K)
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(122.25M) (161.82M) (57.51M) (97.01M)
Minority Interest Expense
- - - -
-
Net Income
(122.25M) (161.82M) (57.51M) (97.01M)
Net Income Growth
+18.45% -32.38% +64.46% -68.67%
Net Margin Growth
-298.42% -4,434.72% -50.76% -89.57%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(122.25M) (161.82M) (57.51M) (97.01M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(122.25M) (161.82M) (57.51M) (97.01M)
EPS (Basic)
-2.3588 -2.0521 -0.5421 -0.7015
EPS (Basic) Growth
+38.28% +13.00% +73.58% -29.40%
Basic Shares Outstanding
51.83M 78.86M 106.10M 138.28M
EPS (Diluted)
-2.3588 -2.0521 -0.5421 -0.7015
EPS (Diluted) Growth
+38.28% +13.00% +73.58% -29.40%
Diluted Shares Outstanding
51.83M 78.86M 106.10M 138.28M
EBITDA
(117.18M) (152.61M) (58.79M) (101.74M)
EBITDA Growth
+18.28% -30.23% +61.48% -73.06%
EBITDA Margin
-286.06% -4,182.13% -51.89% -93.94%

Snapshot

Average Recommendation BUY Average Target Price 20.20
Number of Ratings 15 Current Quarters Estimate -0.273
FY Report Date 12 / 2025 Current Year's Estimate -1.191
Last Quarter’s Earnings -0.32 Median PE on CY Estimate N/A
Year Ago Earnings -0.70 Next Fiscal Year Estimate -1.177
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 8 14 13
Mean Estimate -0.27 -0.32 -1.19 -1.18
High Estimates -0.08 -0.27 -1.00 -0.84
Low Estimate -0.39 -0.38 -1.36 -1.62
Coefficient of Variance -26.59 -11.69 -7.50 -19.35

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Wave Life Sciences Ltd - WVE

Date Name Shares Transaction Value
Mar 24, 2025 Christian O. Henry Director 26,615 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $9.13 per share 242,994.95
Mar 24, 2025 Christian O. Henry Director 16,115 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.77 per share 157,443.55
Mar 24, 2025 Christian O. Henry Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Chandra Vargeese See Remarks 362,687 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.48 per share 899,463.76
Mar 6, 2025 Chandra Vargeese See Remarks N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Chandra Vargeese See Remarks N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 7, 2025 Paul B. Bolno President and CEO; Director 338,351 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Paul B. Bolno President and CEO; Director 1,000,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Christopher Francis See Remarks 25,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Christopher Francis See Remarks 151,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Kyle Moran Chief Financial Officer 89,218 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Kyle Moran Chief Financial Officer 252,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Wave Life Sciences Ltd in the News